Latest

10:13
【Samsung S&P Gsci Crude Oil Er Futures Etf (03175.HK) Rises 3.65% in Morning Trade, Turnover at HKD 9.8390 Million】NewTimeSpace News: As of 10:09 on July 8, Samsung S&P Gsci Crude Oil Er Futures Etf (03175.HK) was up 3.65%, with the latest price at HKD 8.950.
Tag： Samsung S&P Gsci Crude Oil Er Futures Etf03175.HKETF
10:08
【ChinaAMC HSI ESG ETF (03403.HK) Rises 1.27% in Morning Trade, AUM at HKD 9.807 Billion】NewTimeSpace News: As of 10:04 on July 8, ChinaAMC HSI ESG ETF (03403.HK) was up 1.27%, with the latest price at HKD 49.300.
Tag： ChinaAMC HSI ESG ETFETF03403.HK
10:04
【Bosera China Reform Hong Kong Central-SOEs High Dividend Yield Index ETF (Listed Class) (03437.HK) Rises 1.91% in Morning Trade, Turnover at HKD 1.2284 Million】NewTimeSpace News: As of 10:01 on July 8, Bosera China Reform Hong Kong Central-SOEs High Dividend Yield Index ETF (Listed Class) (03437.HK) was up 1.91%, with the latest price at HKD 9.355.
Tag： ETFBosera China Reform Hong Kong Central-Soes High Dividend Yield Index Etf(Listed Class)03437.HK
09:59
【Global X Hang Seng TECH ETF (02837.HK) Rises 1.71% in Morning Trade, AUM at HKD 1.930 Billion】NewTimeSpace News: As of 09:56 on July 8, Global X Hang Seng TECH ETF (02837.HK) was up 1.71%, with the latest price at HKD 5.660.
Tag： Global X Hang Seng TECH ETFETF02837.HK
09:55
【Csop Hang Seng China Enterprises Index Daily (2x) Leveraged Product (07288.HK) Rises 4.22% in Morning Trade, Turnover at HKD 3.1260 Million】NewTimeSpace News: As of 09:51 on July 8,Csop Hang Seng China Enterprises Index Daily (2x) Leveraged Product (07288.HK) was up 4.22%, with the latest price at HKD 2.616.
Tag： 07288.HKCsop Hang Seng China Enterprises Index Daily (2x) Leveraged ProductETF
08:39
【INSILICO(03696.HK): Phase III Clinical Trial of Rentosertib for Idiopathic Pulmonary Fibrosis Officially Launched】NewTimeSpace News: InSilico Medicine Cayman TopCo (03696.HK) announced on 8 July that Rentosertib (ISM001-055), an AI-driven TNIK small-molecule inhibitor, has entered Phase III clinical trials for idiopathic pulmonary fibrosis. The trial plans to enrol 320 subjects across 47 clinical centres nationwide, with the primary endpoint being the annual rate of decline in forced vital capacity within 52 weeks. The asset has previously obtained FDA Orphan Drug Designation and NMPA Breakthrough Therapy Designation. The Company cautions uncertainties over business development.
Tag： Insilico03696.HKClinical Trial
08:34
【ZHONG JI LS(00767.HK): Proposed Joint Establishment of RMB1 Billion Healthcare M&A Fund Focused on Longevity Science and Cell Industry】NewTimeSpace News: Zhong Ji Longevity Science Group Limited (00767.HK) announced on 7 July that its wholly-owned subsidiary Shenzhen Zhongji Health Science Co., Limited signed a memorandum of understanding with Shenzhen Zhongtou Huijin Fund Management Co., Ltd. to jointly set up a special M&A fund for the healthcare industry with a proposed size of RMB1 billion, to be raised in three tranches. The fund will target investments in longevity science, cell therapy, anti-ageing biomedicine and premium health management industries. The memorandum is non-binding and the cooperation is subject to further formalisation.
Tag： ZHONG JI LS00767.HKM&A Fund
08:25
【CHERY AUTO(09973.HK): Signed Auto Sales Framework Agreement with Guangdong Ruixun; Aggregate Annual Caps Totalling RMB1.55 Billion for 2026–2028】NewTimeSpace News: Chery Automobile Co., Ltd. (09973.HK) announced on 7 July that it entered into an automobile sales framework agreement with Guangdong Ruixun Automobile Sales Service Co., Ltd. The annual caps are RMB250 million for 2026, RMB500 million for 2027 and RMB800 million for 2028, aggregating RMB1.55 billion. Controlled by Ms. Wang Laichun, the Company’s Non-executive Director, Guangdong Ruixun gives rise to continuing connected transactions. Pricing terms will not be more favourable than those offered to independent third parties. The Group intends to expand domestic market coverage via Ruixun’s sales network.
Tag： CHERY AUTO09973.HKSales Agreement
08:19
【LANCANG TEA(06911.HK): Independent Investigation Confirms Three Incidents Stemmed from Personal Misconduct of Former Senior Executives; Remedial Measures Implemented】NewTimeSpace News: Pu'Er Lancang Ancient Tea Co., Ltd. (06911.HK) announced on 7 July that an independent investigation report confirmed three matters – private lending disputes, bank account freezing and litigation, as well as warehouse inventory shortages – arose from personal irregular conduct of former senior executives Ms. Wang, ex-General Manager, and Mr. Zhang, ex-Director. Relevant involved parties are not connected with the Company. The two executives shall be held accountable for relevant losses, and internal control rectifications have been completed. No other irregularities or undisclosed material matters were identified as of the report date.
Tag： LANCANG TEA06911.HKindependent investigation
08:11
【DKE Holding Company Limited (01770.HK): Delay to H-Share Listing Timetable; Trading Expected to Commence on 9 July】NewTimeSpace News: DKE Holding Company Limited (01770.HK) announced on 7 July that the timetable for its H-share listing has been delayed, as additional time is required to finalise the final offer price announcement and obtain regulatory approvals. Trading of the H-shares is expected to commence on Thursday, 9 July 2026. The Company published its Prospectus on 29 June previously.
Tag： DKEIPO01770.HKIPO Listing Delay
08:06
【JENSCARE-B(09877.HK): LuX-Valve Plus Transcatheter Tricuspid Valve Replacement System Secures EU MDR CE Certification】NewTimeSpace News: Jenscare Scientific Co., Ltd. (09877.HK) announced on 8 July that its self-developed LuX-Valve Plus transcatheter tricuspid valve replacement system has obtained EU MDR CE certification, making it the world’s second approved in-situ transcatheter tricuspid valve replacement product. Over 1,000 clinical implantations have been completed across dozens of countries and regions on five continents globally. The device has received FDA Breakthrough Device designation and entered NMPA’s Special Review Procedure for Innovative Medical Devices. The Company cautions that there is no guarantee of successful product launch and commercialisation.
Tag： JENSCARE-B09877.HKMDR CE certification
07:59
【CHIHO ENV(00976.HK): Initiates Legal Proceedings Over Appointment of Receivers to Subsidiary Shares, Seeking Declaration That Appointments Are Null and Void】NewTimeSpace News: Chiho Environmental Group Limited (00976.HK) announced on 7 July that it has commenced legal proceedings in the High Court of Hong Kong, seeking a declaration that the appointments of receivers over its subsidiary shares are null and void and an injunction restraining the receivers from taking any actions. The Group has held the view that the receivership appointments were invalid, yet the receivers proceeded to enter into a sale agreement for the Scholz Group. The Company’s shares have been suspended from trading since 1 April 2025 and will remain suspended until further notice.
Tag： CHIHO ENV00976.HKLitigation
07:51
【SINO BIOPHARM(01177.HK): Exclusive Licensing Agreement with AstraZeneca for TQC3721, USD200 Million Upfront Payment plus Up to USD1.9 Billion Milestones】NewTimeSpace News: Sino Biopharmaceutical Limited (01177.HK) announced that its subsidiary Chia Tai Tianqing entered into an exclusive licensing agreement with AstraZeneca for TQC3721, an in-house developed PDE3/4 inhibitor. The Group will receive an upfront payment of USD200 million, aggregate development, regulatory and sales milestone payments of up to USD1.9 billion, plus tiered royalties at rates up to double digits based on annual net sales.
Tag： SINO BIOPHARM01177.HKAstraZenecacooperation
07:45
【SKB BIO-B(06990.HK): Proposed Placing of 5.838 Million New H-Shares, Estimated Net Proceeds of Approximately HK$2.723 Billion】NewTimeSpace News: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (06990.HK) announced that it entered into a placing agreement with the placing agents on 8 July 2026. The Company proposes to place 5,838,000 new H-shares at a placing price of HK$470.20 per share, representing a discount of approximately 8.52% to the closing price of HK$514 on the last trading day. The total gross proceeds will be about HK$2.745 billion, with estimated net proceeds of roughly HK$2.723 billion, to be deployed for product R&D, clinical trials, commercialisation and supplementing working capital.
Tag： SKB BIO-B06990.HKH-share placement
07:38
【GUOXIA TECH(02655.HK): Signs Strategic Framework Agreement with Sweden’s Rocmore Energy to Expand European Energy Storage Market】NewTimeSpace News: Guoxia Technology Co., Ltd. (02655.HK) announced that it entered into a Strategic Cooperation Framework Agreement with Rocmore Energy AB at the end of June 2026. The two parties intend to establish a long-term strategic partnership, integrating the Group’s energy storage solutions with Rocmore’s Nordic projects to jointly serve the Nordic region and broader European markets.
Tag： GUOXIA TECH02655.HKstrategic cooperation
22:08
【CVTE Resubmits HKEX Listing Application for the Third Time; seewo Education Interactive Flat Panels Rank No.1 Globally】NewTimeSpace News: Guangzhou Shiyuan Electronic Technology Company Limited (002841.SZ) submitted its third listing application to the Hong Kong Stock Exchange on 7 July, with CICC and GF Securities acting as joint sponsors. According to Frost & Sullivan data, the Company’s seewo-branded education interactive flat panels captured a 17.0% global market share by revenue, ranking first worldwide in 2025; its MAXHUB-branded conference interactive flat panels held a 25.0% market share in mainland China (1st) and 8.7% globally (2nd); LCD display driver control boards secured a 24.4% global market share by shipment volume, topping the world ranking.
Tag： CVTE002841.SZA+HIPO
21:58
【JIANGXI COPPER(00358.HK): Chairman Zheng Gaoqing Resigns Upon Reaching Statutory Retirement Age】NewTimeSpace News: Jiangxi Copper Company Limited (00358.HK) announced that the Board of Directors received a written resignation notice from Executive Director Mr. Zheng Gaoqing on 7 July 2026. Having reached the statutory retirement age, Mr. Zheng tendered his resignation from the posts of Chairman, Executive Director, Chairman of the Nomination Committee and Chairman of the ESG Development Committee, and will cease to hold any position within the Company.
Tag： JIANGXI COPPER00358.HKretire
21:39
【NANHUA FUTURES(02691.HK): Resolution to Close Harbin Business Department; Businesses to Be Undertaken by Heilongjiang Branch】NewTimeSpace News: Nanhua Futures Co.,Ltd. (02691.HK) announced that to further optimise its network layout of business outlets and integrate operating resources, the Company has resolved to close its Harbin Business Department, with all its businesses to be taken over by the Heilongjiang Branch.
Tag： NANHUA FUTURES02691.HKBusiness Department Closure
21:30
【NEXCHIP(02249.HK): English Corporate Name Changed to Nexchip Semiconductor Corporation】NewTimeSpace News: Hefei Nexchip Integrated Circuit Co., Ltd. (02249.HK) announced that the Companies Registry of Hong Kong has issued a Certificate of Registration of Change of Name for a Registered Non-Hong Kong Company. The Company’s English name has been altered from “Nexchip Semiconductor (China) Limited” to “Nexchip Semiconductor Corporation”, with effect from 6 July 2026.
Tag： Nexchip02249.HKCorporate Name Change
21:27
【HENGRUI PHARMA (01276.HK): SHR-4685 Injection Obtains Clinical Trial Approval for Advanced Solid Tumours】NewTimeSpace News: Jiangsu Hengrui Pharmaceuticals Co.,Ltd (01276.HK) announced that its subsidiary Suzhou Shengdiya Biopharmaceuticals has received the Drug Clinical Trial Approval Letter for SHR-4685 Injection issued and approved by the National Medical Products Administration (NMPA), authorising monotherapy clinical trials of the product in patients with advanced solid tumours. This innovative anti-tumour drug is independently developed by the Group, and no similar drugs have been approved for marketing at home or abroad to date.
Tag： HENGRUI PHARMA01276.HKClinical Trial Application
Previous1..210211 212213214..479     479 pages total
×
Share to WeChat

Open WeChat, use "Scan," and share to my Moments